VivoSeq
Metabolic & Endocrine

Metabolic Syndrome

161

Pipeline Programs↗

19

Active Trials↗

52

Companies Involved↗

Metabolic Syndrome is a highly competitive landscape with 161 programs across 52 companies. The most active players are Luye Pharma Group Ltd., E-Star BioTech, LLC, Liminal BioSciences Ltd.. 59 therapies are approved with 25 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

77/100

Pipeline Velocity

19/100

Mech. Concentration

10/100

Completion Rate

84/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Luye Pharma Group Ltd. logo

Luye Pharma Group Ltd.

1 program

Phase 1E

E-Star BioTech, LLC

1 program

Phase 1L

Liminal BioSciences Ltd.

2 programs

Phase 2I

Inversago Pharma Inc.

1 program

Phase 2I

Immunex

1 program

Phase 2N

Neurim Pharmaceuticals Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical35

Pravastatin

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Irbesartan

Sanofi

Telmisartan

Boehringer Ingelheim

Statin

Bristol-Myers Squibb

Sitagliptin

Zydus Therapeutics Inc.

Phase 17

Indomethacin

Life Extension Foundation Inc.

Spironolactone

Pfizer

Follicle Stimulating Hormone

IBSA Institut Biochimique SA

Zoladex

Luye Pharma Group Ltd.

Anastrozole Pill

Massachusetts General Hospital

Phase 235

Etanercept

Immunex

Melatonin

Neurim Pharmaceuticals Ltd.

Resveratrol

National Cancer Institute (NCI)

Acipimox

Boehringer Ingelheim

Vericiguat

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 325

Topiramate

Wim Janssens

Acarbose

Bayer

Metformin Hydrochloride

Boehringer Ingelheim

Berberine

Xijing Hospital of Digestive Diseases

Rimonabant

Sanofi

Approved59

Diltiazem

Bausch Health Americas, Inc.

Secukinumab

Novartis

Methotrexate

Alnylam Pharmaceuticals

ATAZANAVIR

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Niacin

AbbVie

Analysis

Modality Breakdown

97%

Small molecule

182 of 187 classified programs — the dominant modality here.

3%ALL OTHERSPeptide21%Monoclonal antibody1<1%Protein / enzyme1<1%Vaccine1<1%

Small molecule leads; the ring shows all 187 classified programs, each share of the total. Modality classified for 100% of 191 pipeline programs.

Analysis

Trial Status

202

clinical trials

Completed132 · 65%
Unknown status25 · 12%
Terminated17 · 8%
Recruiting13 · 6%
Withdrawn6 · 3%
Enrolling by invitation2 · 1%
Other7 · 3%

Clinical Trials

Trial Activity

202 trials

Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome
Recruiting·UUniversity of Virginia·Phase 4·NCT04575844·80 enrolled
Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment
Recruiting·CCollegium Medicum w Bydgoszczy·Phase 3·NCT05905965·200 enrolled
Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome
Recruiting·UUniversity of Colorado, Denver·Phase 1·NCT06414096·5 enrolled
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
Recruiting·NNewAmsterdam Pharma·Phase 3·NCT07219602·300 enrolled
Effect of Bariatric Surgery Versus Medical Therapy on Metabolic Syndrome
Recruiting·TThird Military Medical University·N/A·NCT05363059·200 enrolled
Effect of Celery Seed on the Components of Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
Recruiting·UUniversity of Guadalajara·Phase 2·NCT06061926·28 enrolled
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT06686537·20 enrolled
Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota.
Recruiting·NNanjing First Hospital, Nanjing Medical University·Phase 4·NCT07306988·120 enrolled
COMMETS- Combination MCI Metabolic Syndrome
Recruiting·RRutgers, The State University of New Jersey·Phase 2·NCT06072963·80 enrolled
Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome
Recruiting·UUniversity Medical Center, Kazakhstan·Phase 4·NCT06410352·220 enrolled
To Compare the Effects of Herbal Medicines With Traditional Allopathic Medicines in Cases of Patients With Metabolic Syndrome
Recruiting·HHamdard University·N/A·NCT06515652·200 enrolled
Integrated Traditional Chinese Medicine Day Care Program for Metabolic Syndrome
Recruiting·—·Phase 1/2·NCT06703788·200 enrolled
Effects of 14-Day Metformin Withdrawal on OGTT-Derived Insulin Sensitivity in Adults With Metabolic Syndrome: A Randomized Controlled Trial
Recruiting·UUniversity of Castilla-La Mancha·Preclinical·NCT07659444·28 enrolled
Reprometabolic Syndrome Mediates Subfertility in Obesity
Active, not recruiting·UUniversity of Colorado, Denver·N/A·NCT02653092·84 enrolled
Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders. A Double-blind Placebo-controlled Trial.
Active, not recruiting·MManuel Jesús Cuesta Zurita·N/A·NCT07371325·36 enrolled
Page 1 of 14

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)